A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE
- Conditions
- Recurrent or advanced/metastatic solid tumors who are immunotherapy naive and may or may not have been treated with prior therapy for their disease.MedDRA version: 21.0Level: LLTClassification code: 10019828Term: Hepatocellular carcinoma non-resectable Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10027480Term: Metastatic malignant melanoma Class: 100000004864MedDRA version: 20.1Level: LLTClassification code: 10025048Term: Lung cancer non-small cell recurrent Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10029520Term: Non-small cell lung cancer stage IIIA Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10025650Term: Malignant melanoma Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027150Term: Melanoma malignant Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10038394Term: Renal cancer stage IV Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027481Term: Metastatic melanoma Class: 10029104
- Registration Number
- CTIS2022-502716-37-00
- Lead Sponsor
- Incyte Corp.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 328
Ability to comprehend and willingness to sign a written ICF for the study., Age 18 years or older inclusive at the time of signing the ICF., Prior systemic therapy, diagnoses, and disease settings as follows: a. Immunotherapy naive b. Measurable disease per RECIST v1.1 c. One of the following disease settings: see protocol, ECOG performance score of 0 or 1 (except for UC, where a score of up to 2 is permitted)., Life expectancy > 3 months, Willingness to avoid pregnancy or fathering children
Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of disease recurrence for 3 years since initiation of that therapy., Presence of gastrointestinal conditions that may affect drug absorption, as well as those that interfere with gastrointestinal transit, Any autoimmune disease requiring systemic treatment in the past 5 years, including corticosteroids of a daily dose exceeding 10 mg of prednisone or equivalent, Diagnosis of primary immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent, HIV infection and any one or more of the following: CD4+ T-cell count < 200 cells/µL, detectable viral load per parameters of assay, or antiretroviral therapy regimen containing moderate or potent CYP3A4/CYP3A5 inhibitors or inducers, Active infection requiring systemic therapy, with the exception of HIV and hepatitis, History of organ transplantation, including allogeneic stem cell transplantation., Known hypersensitivity or severe reaction to any component of study drug or formulation components., Postoperative complications preventing the participant from adhering protocol assessments and procedures., Receipt of systemic antibiotics within 28 days of first dose of study treatment., Probiotic usage is prohibited during screening and throughout the study treatment period., CNS metastases requiring treatment and/or leptomeningeal disease., Received a live vaccine within 28 days of the planned start of study drug. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, some shingles, yellow fever, rabies, BCG, and typhoid vaccines. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live-attenuated vaccines and are not allowed. Note: If enrolled, participants should not receive live vaccine during the study and up to 28 days after the last dose of study drug., Treatment with moderate and potent CYP3A4/CYP3A5 inhibitors or inducers, Unable to be weaned off of a prohibited medication before the initiation of study treatment., Participants with laboratory values at screening as defined in the protocol, Clinically significant ECG abnormality, including average QTcF interval > 480 milliseconds, Active HBV or HCV as follows (testing must be performed): a.Detectable HBV DNA (viral load) and HBsAg. b. Participants with chronic HBV infection with active disease who meet the criteria for anti-HBV therapy are required to be on a suppressive antiviral therapy prior to initiation of study treatment. c. Active HCV is defined as a positive HCV antibody result and quantitative HCV RNA (viral load) result greater than the lower limit of detection, Pregnant, expecting to conceive, or breastfeeding or expecting to father children, Any condition that would, in the investigator's judgment, interfere with full participation in the study, The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health Code., Toxicity from prior therapy that has not recovered to = Grade 1 or baseline, Prior receipt
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary end point(s): Objective response, defined as having a best overall response of confirmed CR or PR by investigator assessment per RECIST v1.1., Incidence of TEAEs, assessed by physical examinations, changes in vital signs and ECGs, and analysis of clinical laboratory samples., Incidence of TEAEs leading to dose interruption, dose reduction, or study drug discontinuation.;Main Objective: To determine the safety, tolerability, and preliminary efficacy of INCB099280 400 mg BID, 600 mg BID, and 800 mg BID in participants with advanced solid tumors.;Secondary Objective: To determine the efficacy of INCB099280 400 mg BID, 600 mg BID, and 800 mg BID with respect to disease control and response duration in participants with advanced solid tumors., To characterize the INCB099280 PK in plasma in participants with advanced solid tumors.
- Secondary Outcome Measures
Name Time Method